8
Feb
2019

Azar Angles for a Deal Pharma Can Live With, Macrogenics’ Big Break, & Sanofi Scraps 38 R&D Programs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup